Get all premium features to the best stock analysis tool

Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform

• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit • NIH-funded project leverages collaborators' expertise in single-molecule proteomics and protein isoform quantification to advance high-resolution cancer isoform analysis

Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference

SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 46th Annual Health Care Conference.

Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging

• Buck Institute's deployment of Nautilus' instrument generates tau proteoform data, providing external validation of the company's next-generation single-molecule proteomics platform  • Joint research results show high reproducibility across sites and insight into novel tau biology, signaling a fundamental shift in how proteomics technology can advance human health and longevity • Data presentation at the 2025 HUPO World Congress seminar “Redefining Proteomics with Single-Molecule Iterative Mapping” on November 10

Nautilus Biotechnology Reports Second Quarter 2025 Financial Results

SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025.